Ann: Bonus Options Prospectus, page-111

Basically yes. This is explained in some detail in yesterday’s presentation, but basically VO2Peak is able to detect significant change in heart damage in nearly half the patient treated with an anthracycline. Even more importantly, the change in VO2Peak directly impacts the patient’s quality of life. The end result is we can see clinically significant results from trials with as few as 30 patients, rather than the 1000 or more that would be required using LVEF change as an endpoint.

How VO2Peak is able to detect the damage anthracycline causes so much better than other approaches like LVEF is a very interesting question. The best explanation is VO2Peak is a measure of the entire cardiovascular system, not just one component. Anthracyclines damage every part of the cardiovascular system, not just the heart, and what seem like small changes in each part add up to a large total.

The VO2Peak discovery has probably added more value to Race than anything other than RC220. I would place it ahead of the m6A/FTO discovery in terms of importance to Race. I can’t even claim credit for its discovery as it was brought to my attention by a shareholder - we all owe this person a huge thanks.